Donald Engelman
Donald Max Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences, a fellow of the National Institutes of Health, and has been a Guggenheim fellow. He served as the editor of the Annual Review of Biophysics and Biophysical Chemistry (1984–1993).
Donald Max Engelman | |
|---|---|
| Alma mater | |
| Awards | |
| Website | medicine |
| Born | 1941 |
| Education | Reed College, Yale University |
| Awards | Guggenheim fellow |
| Scientific career | |
| Fields | Cancer drugs and treatments |
| Institutions | Yale University |
| Thesis | Solubilization and Aggregation Properties of Membrane Components from Mycoplasma laidlawii' (1968) |
| Doctoral students | Mark A. Lemmon |
He is a director of the Stryker Corporation. He is involved in the creation of new cancer drugs and treatments. For example, Engelman is involved in research to use peptides to aid in destroying tumors.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.